|1.||Dimmock, Jonathan R: 3 articles (01/2009 - 04/2004)|
|2.||Lakshmikuttyamma, Ashakumary: 3 articles (01/2009 - 04/2004)|
|3.||Sharma, Rajendra K: 3 articles (01/2009 - 04/2004)|
|4.||Selvakumar, Ponniah: 3 articles (01/2009 - 04/2004)|
|5.||Hannig, Gerhard: 3 articles (04/2006 - 08/2005)|
|6.||Thompson, Charles D: 3 articles (04/2006 - 08/2005)|
|7.||Westlin, William F: 3 articles (04/2006 - 08/2005)|
|8.||Wongkham, Chaisiri: 2 articles (01/2012 - 01/2007)|
|9.||Araki, Norie: 2 articles (01/2012 - 01/2007)|
|10.||Wongkham, Sopit: 2 articles (01/2012 - 01/2007)|
01/01/2008 - "Inhibition of MetAP-2 in blood and tissues correlated with protection against PG-PS-induced arthritis. "
01/01/2008 - "The important role that MetAP-2 has in the pathophysiological disease processes of PG-PS arthritis provides a strong rationale for evaluating PPI-2458 as a disease modifying antirheumatic treatment for rheumatoid arthritis."
01/01/2012 - "This review article mainly discussed the development of MetAP-2 inhibitors in cancer therapy and also summarized their structure-activity relationships."
01/01/2012 - "MetAP-2 inhibition can induce G1 cell cycle arrest, cytostasis in tumor cells in vitro and inhibition of tumor growth in vivo. "
01/01/2012 - "The development of MetAP-2 inhibitors in cancer treatment."
04/01/2006 - "Methionine aminopeptidase 2 and cancer."
03/10/2005 - "Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model."
05/01/2009 - "PPI-2458 [(1R)-1-carbamoyl-2-methyl]-carbamic acid-(3R,3S,5S, 6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)oxiranyl]-1-oxaspiro(2*5)oct-6-yl ester], a new fumagillin derivative known to inhibit methionine aminopeptidase 2 (MetAP-2) and endothelial proliferation at the late G(1) phase, was evaluated in CIA rats to study its potential to involute synovitis. "
01/01/2007 - "Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target."
01/01/2012 - "Methionine aminopeptidase 2 (MetAP2), a proteolytic enzyme that removes the N-terminal methionine from newly synthesized cellular proteins, plays roles in the development of various cancers and has been found to be over-expressed in cholangiocarcinoma (CCA). "
04/01/2005 - "Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models."
10/18/2005 - "We will also discuss a variety of vascular inhibition strategies that have been used in neuroblastoma preclinical models including specific inhibition of vascular endothelial growth factor (VEGF) and methionine aminopeptidase 2 (MetAP2). "
04/01/2005 - "We previously showed that the antiangiogenic compound TNP-470, an irreversible methionine aminopeptidase 2 (MetAP2) inhibitor, suppressed local and disseminated human neuroblastoma growth rates in murine models but had significant associated toxicity at the effective dose. "
|3.||Proteins (Proteins, Gene)
|8.||carbamic acid (ammonium carbamate)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)